Newswire (Published: Friday, April 28, 2017, Received: Thursday, April 20, 2017, 7:53:50 PM CDT)

Word Count: 373

Studies from University of Palermo Update Current Data on Prostate Cancer (The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study)

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting from Palermo, Italy, by NewsRx journalists, research stated, "To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. A total of 60 patients were enrolled."

The news correspondents obtained a quote from the research from the University of Palermo, "Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant correlation between PSA response and overall survival was also noted. The regression analysis revealed PSA level to be predictive of overall survival."

According to the news reporters, the research concluded: "Enzalutamide was shown to be an effective and welltolerated therapeutic option in patients with metastatic castration-resistant prostate cancer progressing after docetaxel plus prednisone treatment."

For more information on this research see: The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. Anticancer Research, 2017;37(3):1475-1480. Anticancer Research can be contacted at: Int Inst Anticancer Research, Editorial Office 1ST Km Kapandritiou-Kalamou Rd Kapandriti, PO Box 22, Athens 19014, Greece. (International Institute of Anticancer Research - www.iiar-anticancer.org/; Anticancer Research - www.iiar-anticancer.org/main.php?id=2)

Our news journalists report that additional information may be obtained by contacting G. Cicero, University of Palermo, Sect Med Oncol, Dept. of Surg Oncol & Oral Sci, Palermo, Italy. Additional authors for this research include R. De Luca, P. Dorangricchia and F. Dieli (see also Oncology - Prostate Cancer).

Keywords for this news article include: Palermo, Italy, Europe, Metastatic Prostate Cancer, Prostate-Specific Antigen, Enzymes and Coenzymes, Prostatic Neoplasms, Oncology, University of Palermo.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Southern Europe
Greece
Italy
Europe
Palermo
Athens

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Drug Testing and Approval Process
      Treatments and Therapies
            Chemotherapy
            Medicinal Drugs
                  Drug Testing and Approval Process